See the DrugPatentWatch profile for vascepa

Based on the information provided, I am unable to directly provide the annual vascepa prescription limit as it is not explicitly stated in the source. However, I can provide information regarding vascepa and its patent status.

Vascepa (icosapent ethyl) is a medication used to lower triglyceride levels in the blood. It is manufactured by Amarin Pharma Inc. According to DrugPatentWatch.com [1], Vascepa's patent expired on December 11, 2020, in the United States. Post-patent expiration, generic versions of the drug can potentially become available, which may impact prescription limits and costs.

It is essential to consult with a healthcare provider or pharmacist for specific information regarding vascepa prescription limits and any potential changes due to patent expiration.

Sources:
[1] https://www.drugpatentwatch.com/drugs/vascepa